

Waters unveils high resolution mass spec products to accelerate drug development

07 June 2022 | News

New Xevo G3 quadrupole time-of-flight mass spectrometer that is up to 10X more sensitive than its predecessori for qualitative and quantitative analyses of challenging molecules

Waters Corporation has unveiled new instruments, software and product enhancements to drive drug discovery and development. The products include the new Xevo G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect software platform and an electrospray ionization source for the high-resolution Waters SELECT SERIES Multi-Reflecting Time of Flight (MRT) mass spectrometer.

The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables.

The CONFIRM Sequence app on the waters_connect software platform helps scientists using a Waters LC-MS System to confirm the nucleic acid sequence of therapeutics and identify impurities that could compromise product safety and efficacy.

The Waters SELECT SERIES MRT System is now compatible with UPLC-MS with an available electrospray ionization (ESI) source. Coupling the high resolution MRT System with the ESI source enables scientists to accurately resolve and measure low (<200 ppb) concentrations of sample analytes at UPLC acquisition speeds for metabolomics, metabolite identification or peptide mapping applications.